HI
FOLD

HBK Investments’s Amicus Therapeutics FOLD Stock Holding History

HBK Investments’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127M Sell
8,783,448
-6,466,552
-42% -$92.7M 1.29% 22
2025
Q4 		$217M Buy
+15,250,000
New +$150M 1.71% 19
2015
Q4 		– Sell
-91,300
Closed -$1.28M – 1022
2015
Q3 		$1.28M Buy
+91,300
New +$1.43M 0.01% 525

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HBK Investments's FOLD Position: Q1 2026 in Review

HBK Investments reduced its Amicus Therapeutics (FOLD) stake by 42% in Q1 2026, selling an estimated $92.7M and leaving 8,783,448 shares worth $127M. The position accounts for 1.29% of the portfolio, ranked #22.

HBK Investments first reported a position in FOLD in Q3 2015 and has held it in 3 quarters since. The position peaked at $217M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • HBK Investments held 8,783,448 shares of Amicus Therapeutics worth $127M as of Q1 2026.
  • HBK Investments sold 6,466,552 Amicus Therapeutics shares in Q1 2026, an estimated $92.7M.
  • Amicus Therapeutics made up 1.29% of HBK Investments's portfolio in Q1 2026, its #22 holding.
  • HBK Investments first reported a position in Amicus Therapeutics in Q3 2015 and has held it in 3 quarters since.
  • HBK Investments's Amicus Therapeutics position peaked at $217M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on HBK Investments's 13F filing for Q1 2026, filed 15 May 2026.